Elaine Chen , 2025-08-12 16:35:00
Insmed on Tuesday received Food and Drug Administration clearance for the first treatment for a chronic lung disease, opening the biotech up to what could be a multibillion-dollar product.
Insmed will sell the daily pill, brensocatib, under the brand name Brinsupri for bronchiectasis. The approval comes after the treatment succeeded in one of last year’s most closely watched Phase 3 trials.
The company estimates the drug can deliver peak sales of $5 billion, making it a growth driver that could help propel it into a major biotech like Vertex Pharma. The company has also filed for the drug to be approved in Europe and the U.K. and plans to file in Japan.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.